Inhibikase Therapeutics's chart data is dated 2026-10-08. There is no active technical signal. There are 5 published signal records.
Inhibikase Therapeutics last closed at $1.91 (-1.55%) on 2026-10-08. Listed on Nasdaq. Trailing 12 months PER is -5.5×. Its overall grade ranks 293 of 738 stocks in Healthcare.
About this company
Inhibikase Therapeutics last closed at $1.91 (-1.55%) on 2026-10-08. Listed on Nasdaq.
Details →Reported results
Position in sector
Healthcare · Overall B+ · 293/738
Valuation grade A
Related stocks
- NovartisCompetitor
파킨슨병·신경퇴행성 질환 치료제 개발에서 경쟁 가능성이 큰 글로벌 제약사
- AbbVieCompetitor
신경과/염증·면역 질환 파이프라인을 보유한 대형 제약사로 경쟁 환경에 영향
- RocheCompetitor
중추신경계 질환 및 바이오의약품 분야의 대형 경쟁사
About Inhibikase Therapeutics
- What technical signals does Inhibikase Therapeutics (IKT) have?
- Inhibikase Therapeutics current technical signals: no active technical signal.
- Is Inhibikase Therapeutics a cup-and-handle pattern?
- No. Inhibikase Therapeutics has no valid Cup signal right now.
- What published figures are available for Inhibikase Therapeutics?
- Market cap: $230.92M. Trailing 12 months PER: -5.5×. Latest quarter PBR: 2.17×. Dividend yield: 0.00%.
Like these rules? Backtest them.
Run this signal on this ticker in the free backtest builder — same window, no install.
Backtest this rule ↗Turn what you saw on this name into a strategy
Ask Q about Inhibikase Therapeutics, or open the plan table on the main site.
From the names you found to a trading rule
Tell Q about the stocks you found to place orders with your conditions.